Related Experiment Videos
Trends of congestive heart failure epidemiology: contrast with clinical trial results
L J Dominguez1, G Parrinello, P Amato
1Istituto di Clinica Medica, Università degli Studi, Palermo.
Insights
Congestive heart failure (CHF) remains a significant public health issue with high mortality rates, despite treatment advances. Improved survival from related conditions like coronary artery disease and hypertension contributes to its growing prevalence.
Area of Science:
- Cardiology
- Public Health
- Epidemiology
Background:
- Congestive heart failure (CHF) is a growing public health concern, causing significant morbidity and mortality.
- Increasing incidence is linked to an aging population and better management of coronary artery disease and hypertension.
- Coronary artery disease and hypertension are the primary causes of CHF, with hypertension rising in developing nations.
Purpose of the Study:
- To highlight the public health impact of congestive heart failure.
- To discuss the epidemiological trends and etiological factors of CHF.
- To review the current treatment landscape and its impact on CHF prognosis.
Main Methods:
- Literature review and analysis of epidemiological data on CHF prevalence and mortality.
- Examination of etiological factors including coronary artery disease and hypertension.
- Assessment of the impact of current therapeutic advancements on patient outcomes.
Main Results:
- CHF affects 0.4-2% of the general population, with increasing hospital admissions.
- Mortality remains high, with a 4-year survival rate for diagnosed patients and 1-year for severe cases.
- Despite therapies like ACE inhibitors, overall community prognosis has not significantly improved.
Conclusions:
- Congestive heart failure presents a substantial and escalating public health challenge.
- Current therapeutic advancements have not yet translated into improved community-level prognosis for CHF.
- Wider implementation of ideal treatment and follow-up conditions is needed to impact CHF outcomes.
Abstract:
Congestive heart failure (CHF) is an important and growing public health problem and the cause of substantial morbidity and mortality. Its increasing incidence and prevalence may be in part explained by the progressive aging of the world population. The improvement in coronary artery disease and hypertension treatment allows the individuals to lie longer and develop CHF. Indeed, the most common etiology of CHF is coronary artery disease, the leading cause of cardiovascular morbidity and mortality worldwide, and the second cause of CHF is hypertension which is still markedly increasing in developing countries. Estimates of prevalence of CHF are 0.4 to 2% of the general population. The number of hospital admissions for CHF has also been steadily increasing. Half of the patients carrying a diagnosis of CHF will die within 4 years and patients with severe CHF will die within 1 year. At present, there is no evidence that the prognosis of heart failure in the community has changed despite the advances in therapy over the past decades, such as the demonstration that angiotensin-converting enzyme inhibitors and other vasodilators improve the clinical signs and symptoms of patients with CHF, reduce mortality and slow the progression of myocardial dysfunction. Nevertheless, the overall mortality from this condition remains very high. It is possible that the results of the trials have not yet been evidenced in the majority of patients with CHF because the ideal conditions, treatment and follow-up in the trials are not yet widely achieved in the population.